Drug intelligence / Profile preview

HND042

Development stage: Preclinical
Lead developer: Handa Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

HND042 is a preclinical-stage small molecule tyrosine kinase inhibitor (TKI) being developed by Handa Pharma for the treatment of various oncology indications. Part of the company's Hand Energetics pipeline, the drug is designed to target tyrosine kinases, which are enzymes that play a critical role in the signaling pathways responsible for cell growth, differentiation, and survival. By inhibiting these kinases, HND042 aims to disrupt the proliferation of malignant cells. The program is currently in the proof-of-concept stage of development.

Targets

PTK (Tyrosine-protein kinase)

Beyond the preview

Go deeper on HND042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HND042.

Explore the full profile